Titan Pharmaceuticals, Inc. (TTNP)

NASDAQ: TTNP · Real-Time Price · USD
3.590
-0.060 (-1.64%)
Apr 23, 2025, 4:00 PM EDT - Market closed
-1.64%
Market Cap 3.38M
Revenue (ttm) n/a
Net Income (ttm) -4.71M
Shares Out 914.23K
EPS (ttm) -5.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,653
Open 3.600
Previous Close 3.650
Day's Range 3.530 - 3.600
52-Week Range 3.030 - 14.800
Beta 1.28
Analysts n/a
Price Target n/a
Earnings Date May 14, 2025

About TTNP

Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 18, 1996
Employees 4
Stock Exchange NASDAQ
Ticker Symbol TTNP
Full Company Profile

Financial Performance

Financial Statements

News

Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the “Purchase Agre...

12 days ago - GlobeNewsWire

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qual...

5 months ago - GlobeNewsWire

TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Titan Pharmace...

8 months ago - Business Wire

Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “M...

8 months ago - GlobeNewsWire

Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that by letter dated January 24, 2024, the Company ...

1 year ago - GlobeNewsWire

Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

SOUTH SAN FRANCISCO, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that its Board of Directors has approved a 1-for-20...

1 year ago - GlobeNewsWire

Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato' Seow Gim Shen and Brynner Chiam ...

1 year ago - GlobeNewsWire

Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreem...

1 year ago - GlobeNewsWire

Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

Company to receive $2 million in upfront payments, with the potential to receive up to $50 million in milestone payments and single digit royalty payments on future net sales Company to receive $2 mil...

1 year ago - GlobeNewsWire

Titan Pharmaceuticals Provides Shareholder Update

SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") is pleased to report that it has entered a non-binding letter of intent to comple...

2 years ago - GlobeNewsWire

UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.

SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has granted an exclusive license to Ocular Therapeutix In...

2 years ago - GlobeNewsWire

Titan Pharmaceuticals Announces Board Expansion and Management Changes

SOUTH SAN FRANCISCO, Calif. , Aug. 16, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has expanded its Board of Directors (the "Boar...

2 years ago - PRNewsWire

Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant

SOUTH SAN FRANCISCO, Calif. , July 5, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has ...

3 years ago - PRNewsWire

Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.

NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- David E. Lazar, Chief Executive Officer of Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), one of the largest stockhold...

3 years ago - GlobeNewsWire

Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.

NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), today filed a Schedule 13D announcing its acquisition of approximately...

3 years ago - GlobeNewsWire

Titan Pharmaceuticals Raises $5.5M Via Equity

Titan Pharmaceuticals Inc TTNP has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. Thousands of new traders are learning the ins and outs on how to find prof...

3 years ago - Benzinga

Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market

SOUTH SAN FRANCISCO, Calif., Feb. 2, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a securities purchase agreement...

3 years ago - PRNewsWire

Titan Pharmaceuticals to Explore Strategic Alternatives

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has commenced a process to explore and evaluate...

3 years ago - PRNewsWire

Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021

SOUTH SAN FRANCISCO, Calif., Nov. 8, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, in a presentation given today at the Society for Neurosc...

3 years ago - PRNewsWire

Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. announced that data from continuing studies of its ProNeura®-based TP-2021 implant in an established animal model ...

3 years ago - PRNewsWire

Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received funding from the Bill & Melinda Ga...

3 years ago - PRNewsWire

Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a research and option license ...

3 years ago - PRNewsWire

Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," form...

4 years ago - PRNewsWire

Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K

SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ --  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended Decem...

4 years ago - PRNewsWire

Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high pote...

4 years ago - PRNewsWire